Valiant Laboratories, the material subsidiary of Valiant Organics, has filed a draft red herring prospectus with the capital markets regulator Securities and Exchange Board of India (SEBI) for fund raising via initial public offering. "The filing draft papers dated June 5 is in relation to its proposed IPO by way of fresh issue of up to 1,15,56,000 equity shares," the company said in its filing to exchanges.
Valiant Laboratories has proposed a listing of shares on BSE Limited, and the National Stock Exchange of India.
It is an active pharmaceutical ingredient (API) manufacturing company, having a focus on the manufacture of paracetamol.
Valiant Organics share price settled at Rs 609.95 on the BSE, up 1 percent on June 6.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
